Locoregional Recurrence in p16‐Positive Oropharyngeal Squamous Cell Carcinoma After TORS

Autor: Bert W. O'Malley, Ryan M. Carey, Justin R. Shinn, Karthik Rajasekaran, Leila J. Mady, Robert M. Brody, David Shimunov, Roger B. Cohen, Jason G. Newman, Alexander Lin, Joshua Bauml, Devraj Basu, Gregory S. Weinstein, John N. Lukens, Steven B. Cannady
Rok vydání: 2021
Předmět:
Male
Natural Orifice Endoscopic Surgery
Oncology
medicine.medical_specialty
medicine.medical_treatment
Oropharynx
Salvage therapy
Alphapapillomavirus
Lower risk
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Robotic Surgical Procedures
Internal medicine
Transoral robotic surgery
medicine
Adjuvant therapy
Humans
Oropharyngeal squamous cell carcinoma
030223 otorhinolaryngology
Cyclin-Dependent Kinase Inhibitor p16
Aged
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
business.industry
Papillomavirus Infections
fungi
Head and neck cancer
Neck dissection
Chemoradiotherapy
Adjuvant
Middle Aged
medicine.disease
Oropharyngeal Neoplasms
Otorhinolaryngology
030220 oncology & carcinogenesis
Female
Radiotherapy
Adjuvant
Neoplasm Recurrence
Local
business
Adjuvant
Zdroj: The Laryngoscope. 131
ISSN: 1531-4995
0023-852X
Popis: OBJECTIVE To analyze the patterns, risk factors, and salvage outcomes for locoregional recurrences (LRR) after treatment with transoral robotic surgery (TORS) for HPV-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC). STUDY DESIGN Retrospective analysis of HPV+ OPSCC patients completing primary TORS, neck dissection, and NCCN-guideline-compliant adjuvant therapy at a single institution from 2007 to 2017. METHODS Features associated with LRR, detailed patterns of LRR, and outcomes of salvage therapy were analyzed. Disease-free survival (DFS) and overall survival (OS) were calculated for subgroups of patients receiving distinct adjuvant treatments. RESULTS Of 541 patients who completed guideline-indicated therapy, the estimated 5-year LRR rate was 4.5%. There were no identifiable clinical or pathologic features associated with LRR. Compared to patients not receiving adjuvant therapy, those who received indicated adjuvant radiation alone had a lower risk of LRR (HR 0.28, 95% CI [0.09-0.83], P = .023), but there was no difference in DFS (P = .21) and OS (P = .86) between adjuvant therapy groups. The 5-year OS for patients who developed LRR was 67.1% vs. 93.9% for those without LRR (P
Databáze: OpenAIRE
Externí odkaz: